HomeWebinarsAseptic Process Sampling Risk Mitigation - A Regulatory Perspective

Aseptic Process Sampling Risk Mitigation - A Regulatory Perspective


Increasing validation requirements along with the raise of QbD and PAT have put sterile processes sampling under scrutiny by regulation bodies. Traditional sampling methods have reached their limits while closed sampling methods come of age. Beyond the need to ensure contamination control, the regulatory authorities require compliance in different aspects related to the sampling method of a drug.

This webinar will review the benefits attained from implementing single-use systems. In this objective, these authorities provide guidance on processes helping to reach these requirements (e.g. QbD, PAT, Process validation). Drug manufacturers have the possibility to respond to these expectations through the implementation of single-use systems, instead of common traditional sampling methods, which include the usage of glass bottles or SIP stainless steel valves.

Join this webinar to learn more about the recommendations and requirements stated by these major regulatory authorities regarding the monitoring of the manufacturing process with the execution of sampling. In addition, this webinar will include a review of the benefits attained from implementing single-use systems, therefore reducing the sampling risks compared to traditional methods.
In this webinar you will learn:

  • Key drivers for Aseptic Process Sampling
  • Complexity and Risks of Traditional Sampling Methods
  • Regulatory Recommendations, Corresponding Needs, and how to get there


Janmeet Anant, Ph.D.

Janmeet Anant, Ph.D.


Senior Regulatory Consultant

Janmeet Anant is a senior regulatory consultant, focused on biopharmaceutical manufacturing at MilliporeSigma. Janmeet serves as an executive board member for the Bioprocess Systems Alliance (BPSA) and a member of the Regulatory Governance Team at BioPhorum.

He has more than 20 years of experience, moving through technical application roles for chromatography, filtration, cell culture and, most recently, regulatory consulting. Janmeet has a B.S. in Chemistry and a Ph.D. in Pharmacology.

Marc-Antoine Kaag

Marc-Antoine Kaag


Global Product Manager Sampling

Webinar Information

Pharma and biopharma manufacturing

  • Monoclonal antibody manufacturing
  • Duration:50min

  • Language:English

  • Session 1:presented October 27, 2016

Sign In To Continue

To continue reading please sign in or create an account.

Don't Have An Account?